Clearside Biomedical — Technical Presentation (December 2021)
21 slides from Clearside Biomedical's technical presentation, Dec 21, 2021
Slide 1: OASIS Phase 1/2a Clinical Trial Safety Results
OASIS Phase 1/2a Clinical Trial Safety Results December 21, 2021 Exhibit 99.1
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,”
Slide 3: CLS-AX (axitinib injectable suspension) for Suprachoroidal Use
CLS-AX (axitinib injectable suspension) for Suprachoroidal Use Potential to improve the treatment landscape for wet AMD patients Longer lasting treatment may reduce patient burden from monthly injections Protecting the vitreous and anterior chamber may eliminate symptomatic floaters and other side e
Slide 4: Axitinib: a Highly Potent, Pan-VEGF TKI to Treat Wet AMD
Axitinib: a Highly Potent, Pan-VEGF TKI to Treat Wet AMD Sources: 1. Cabral T et al. Bevacizumab Injection in Patients with Neovascular Age-Related Macular Degeneration Increases Angiogenic Biomarkers. Ophthalmol Retina. 2018 January ; 2(1): 31–37. doi:10.1016/j.oret.2017.04.004. | 2. Lieu et al. Th
Slide 5: Suprachoroidal CLS-AX Demonstrated Targeted Delivery in Preclinical Models
Suprachoroidal CLS-AX Demonstrated Targeted Delivery in Preclinical Models Plasma SCS CLS-AX at or below level of detection Rabbit Model Values: area under the curve ratios, SCS / IVT SCS : 1 mg/eye, 100 µL IVT: 1 mg/eye, 25 µL Single bilateral injection 1-wk rabbit PK studies 11x SCS vs IVT Retina
Slide 6: CLS-AX has Potential for Meaningful Durability
CLS-AX has Potential for Meaningful Durability Therapeutic Levels > IC50 for 6 months after 1.05 mg/eye SCS Injection in Rabbits Rabbit toxicology study with single bilateral suprachoroidal injection of axitinib, 1.05 mg/eye (n=4 eyes/ timepoint) On day 182, mean axitinib levels in the RPE-choroid-s
Slide 7: CLS-AX Phase 1/2a Clinical Trial in Wet AMD
CLS-AX Phase 1/2a Clinical Trial in Wet AMD TRIAL DESIGN AND OBJECTIVES Open-label study with a primary endpoint to evaluate safety and tolerability of escalating single doses of CLS-AX administered through suprachoroidal injection following IVT aflibercept 3 Cohorts of 5 patients each: n=15 Dose-es
Slide 8: Wet AMD History
Wet AMD History Wet AMD Disease Characteristics COHORT 1: 0.03 mg (N=6) COHORT 2: 0.10 mg (N=5) No. of participants 6 5 Bilateral wAMD, n 0 4 Mean duration of wAMD diagnosis (range), months 50.13 (12.4-110.3) 49.78 (24.7-81.3) Mean duration since first wAMD treatment (range), months 50.08 (12.4-110.
Slide 9: Demographics and Characteristics at Baseline
Demographics and Characteristics at Baseline CHARACTERISTICS COHORT 1: 0.03mg (N=6) COHORT 2: 0.10mg (N=5) No. of participants 6 5 Mean age (range), years 81.8 (66-93) 78.2 (65-90) Women, no. (%) 2 (33.3) 3 (60.0) Mean baseline best corrected visual acuity (range), letters 59.0 (29-74) 65.6 (52-75)
Slide 10: Anti-VEGF Treatments up to Years Prior to Screening
Anti-VEGF Treatments up to 3 Years Prior to Screening Source: ADLS (CLSD ADaM), ADPTRT (CLSD ADaM) COHORT 1: 0.03 mg COHORT 2: 0.10 mg
Slide 11: Injection Procedure Questionnaire Responses
Injection Procedure Questionnaire Responses INJECTING PHYSICIAN QUESTION COHORT 1: 0.03 mg (N=6) Cohort 2: 0.10 mg (N=5) Were you able to inject all contents of the syringe? YES, n (%) 6 (100) 5 (100) Needle length used to perform procedure: 900 µm needle, n (%) 6 (100) 5 (100) IF 900 µm NEEDLE WAS
Slide 12: Safety Overview
Safety Overview No study suspension or stopping rules were met No Serious Adverse Events (SAEs) No treatment emergent adverse events (TEAEs) related to aflibercept, CLS-AX or suprachoroidal injection procedure No dispersion of investigational product into the vitreous No adverse events related to in
Slide 13: Prior Anti-VEGF Therapies and Time to Additional Therapy
6 Month Prior Anti-VEGF Therapies and Time to Additional Therapy Source: ADLS (CLSD ADaM), ADPTRT (CLSD ADaM), ADRM (CLSD ADaM) Time to Additional Therapy Number (%) of Participants > 3 months 4 (36.4%) 2 months 6 (54.5%) 1 month 1 (9.1%) SC CLS-AX injection IVT Aflibercept injection Anti-VEGF injec
Slide 14: Reason for Retreatment
Reason for Retreatment COHORT SUBJECT RETREATMENT VISIT REASON FOR RETREATMENT COHORT 1: 0.03 mg (N=6) 5 2 months post CLS-AX BCVA 4 2 months post CLS-AX CST 3 2 months post CLS-AX CST 1 2 months post CLS-AX BCVA COHORT 2: 0.10 mg (N=5) 5 1 month post CLS-AX CST – retreatment criteria not met accord
Slide 15: Individual Best Corrected Visual Acuity Letter Score, by Visit
Individual Best Corrected Visual Acuity Letter Score, by Visit COHORT 1: 0.03 mg COHORT 2: 0.10 mg Source: Clearside data on file.
Slide 16: Mean Best Corrected Visual Acuity Letter Score, Change from Screening
Mean Best Corrected Visual Acuity Letter Score, Change from Screening *Cohort 2 subject 2 discontinued after receiving additional therapy | Source: Clearside data on file. Cohort Screening Baseline Week 4 Week 8 Week 12 Cohort 1, n 6 6 6 6 6 Cohort 2, n 5 5 5 5 4* Cohort Screening Baseline Week 4 We
Slide 17: Individual Central Subfield Thickness, by Visit
Individual Central Subfield Thickness, by Visit Source: Clearside data on file. COHORT 1: 0.03 mg COHORT 2: 0.10 mg
Slide 18: Mean Change Central Subfield Thickness, Change from Screening
Mean Change Central Subfield Thickness, Change from Screening Cohort Screening Baseline Week 4 Week 8 Week 12 Cohort 1, n 6 6 6 6 6 Cohort 2, n 5 5 5 5 4* Cohort Screening Baseline Week 4 Week 8 Week 12 Cohort 1, n 6 6 6 6 2 Cohort 2, n 5 5 5 4 2 *Cohort 2 subject 2 discontinued after receiving addi
Slide 19: OASIS Cohort 1 & 2 Results Support Advancing to Cohort 3
OASIS Cohort 1 & 2 Results Support Advancing to Cohort 3 DURABILITY POST CLS-AX IN HEAVILY PRE-TREATED PATIENTS 4/11 (36%) of patients did not require additional therapy for > 3 months 6/11 (55%) of patients did not require additional therapy for 2 months 1/11 (9%) patient was retreated at 1 month V
Slide 20: Protocol Dosing Change for Cohort 3
Cohort 1 0.03 mg Cohort 2 0.1 mg Cohort 3 0.5 mg Given that this is the first time a tyrosine kinase inhibitor has been injected suprachoroidally in humans, we initiated OASIS with a low dose to establish a foundation for safety. The lack of dose limiting toxicities in Cohorts 1 and 2, along with pr
Slide 21: Nasdaq: CLSD
Nasdaq: CLSD
Clearside Biomedical — Technical Presentation (December 2021) on 6ix